

Chapter 2

Mesenchymal Stem Cells in Clinical Applications

Phuc Van Pham

2.1 Introduction

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, e.g., osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells). MSCs were first discovered by Alexander Maximow, who identified a cell type within the mesenchyme with potential to develop into various types of blood cells. McCulloch and James later revealed the clonal nature of marrow cells in 1963 (Becker et al. 1963; Siminovitch et al. 1963). An ex vivo assay for examining the potential of multipotent marrow clonogenic cells was reported in the 1970s by Friedenstein and colleagues (Friedenstein et al. 1974, 1976). MSCs were determined based on three common characteristics: ability to adhere to culture vessels with a fibroblast-like shape; expression of characteristic markers Stro-1, CD133, CD29, CD44, CD90, CD105 (SH2), SH3, SH4 (CD73), c-kit, CD71, and CD106; and ability to differentiate into specialized cells, e.g., the bone, cartilage, and fat. To easily determine which stem cells are MSCs, in 2006 the International Society of Cellular Therapy defined MSCs with some minimal criteria (Dominici et al. 2006), including:

1. MSCs must be adherent to plastic under standard tissue culture conditions.
2. MSCs must express some specific markers such as CD73, CD90, and CD150 and lack expression of CD14, CD34, CD45 or CD11b, CD79 alpha or CD19, and HLA-DR.
3. MSCs must successfully differentiate into osteoblasts, adipocytes, and chondroblasts under in vitro conditions.

P. V. Pham (✉)

Laboratory of Stem Cell Research and Application, University of Science,
Vietnam National University, Ho Chi Minh City, Vietnam

e-mail: pvphuc@hcmuns.edu.vn




Fig. 2.1 Sources of MSCs. MSCs can be derived from several tissues in the adult or infant human body

The first identified source of MSCs was bone marrow. MSCs are currently isolated from many different tissues in the body, such as the adipose tissue, peripheral blood, umbilical cord blood, banked umbilical cord blood, umbilical cord, umbilical cord membrane, umbilical cord vein, Wharton's jelly of the umbilical cord, placenta, decidua basalis, ligamentum flavum, amniotic fluid, amniotic membrane, dental pulp, chorionic villi of the human placenta, fetal membranes, menstrual blood, breast milk, and urine (Fig. 2.1, Table 2.1).

2.2 How MSCs Can Treat Diseases?

Different than other stem cells, MSCs can be used to treat diseases by two different mechanisms, including tissue repair and immune modulation. While tissue repair is related to the differentiation of multipotent MSCs, immune modulation is a particular property of MSCs. Over the last decades, MSCs have been considered as a feasible source of stem cells for tissue regeneration. It hopes to open the new era of

Table 2.1 Human MSC sources, cell surface markers, and expansion media with serum supplements

Source	Method of isolation	Media	Serum supplement	Cell surface markers		References
				Positive	Negative	
Bone marrow	Ficoll density gradient method	DMEM	FBS	CD73, CD90, CD105, STRO-1	CD14, CD34, CD45, HLA-DR	Mamidi et al. (2012), Otsuru et al. (2013) and Stewart et al. (1999)
	Novel marrow filter device	DMEM-F12				
		ADMEM				
Adipose tissue	Digestion method	DMEM	FBS	CD73, CD090, CD29, CD44, CD71, CD105, CD13, CD166, STRO-1	CD14, CD31, CD34, CD45	Castrechini et al. (2012), El-Kheir et al. (2014) and Gronthos et al. (2001)
	Membrane filtration method	DMEM-LG	FCS			
Amniotic fluid and membrane	Density gradient method	α -MEM	FBS	CD29, CD44, CD90, CD105, CD, SH2, SH3, HLA-DR	CD10, CD14, CD34, HLA-DR	Cai et al. (2010), In 't Anker et al. (2003) and Tsai et al. (2004)
	Digestion method	DMEM/F12				
Dental tissues	Digestion method	α -MEM	FCS	CD29, CD44, CD90, CD105	CD14, CD34, CD45	Huang et al. (2009), Kadar et al. (2009) and Seifirova et al. (2012)
		MEM	FBS			
Endometrium	Digestion method	DMEM-F12	FCS	CD73, CD90, CD105, CD146	CD34, CD45	Schuring et al. (2011)
Limb bud	Digestion method	DMEM-LG	FBS	CD13, CD29, CD90, CD105, CD106	CD3, CD4, CD14, CD15, CD34, CD45, HLA-DR	Jiao et al. (2012)
Peripheral blood	Ficoll density gradient	α -MEM	NBCS	CD44, CD90, CD105, HLA-ABC	CD45, CD133	Ab Kadir et al. (2012)
Placenta and fetal membrane	Digestion method	DMEM-LG	FBS	CD29, CD73, CD90, CD105	CD34, CD45	Raynaud et al. (2012)
Salivary gland	Digestion method (Ringer solution)	DMEM	FCS	CD13, CD29, CD44, CD90, STRO-1	CD34, CD45	Rotter et al. (2008)
Skin and foreskin	Digestion method	DMEM-HG DMEM DMEM-F12	FBS	CD44, CD73, CD90, CD105, CD166, SSEA-4, vimentin	CD34, CD45, HLA-DR	Bartsch et al. (2005) and Riekstina et al. (2008)

(continued)

Table 2.1 (continued)

Source	Method of isolation	Media			Serum supplement	Cell surface markers		References
		DMEM-HG	DMEM	CMRL1660		Positive	Negative	
Sub-amniotic umbilical cord lining membrane	Digestion method				FBS	CD29, CD44, CD73, CD90, CD105	CD34, CD45	Kita et al. (2010) and Moretti et al. (2010)
Synovial fluid	Ficoll density gradient method	α -MEM			FBS	CD44, CD90, CD105, CD147, STRO-1	CD31, CD34, CD45, CD106	Morito et al. (2008)
Wharton's jelly	Enzymatic digestion method	DMEM			FBS	CD73, CD90, CD105	CD14, CD34, CD45, CD79, HLA-DR	Hou et al. (2009)
Menstrual blood	Density gradient centrifugations	α -MEM			FBS	CD56, CD73, CD90, CD105 and CD146	CD14, CD45, HLA-DR	Rossignoli et al. (2013)
Human milk	Centrifugations	DMEM			UCBS	CD44, CD29, SCA-1	CD33, CD34, CD45, CD73	Patki et al. (2010)




Fig. 2.2 Some mechanisms of MSCs in therapeutic application. MSCs are multipotent stem cells; therefore, they can differentiate into some specific cells that can replace some injured cells/damaged adult cells. In another strategy, MSCs can modulate the immune response via some cytokines

stem cell therapy for degenerative diseases. However, the immune modulation capacity of MSCs has been the subject of recent interest over the past several years. The first MSC drug, Prochymal produced by Osiris Therapeutics, was approved in 2012 and is used for immune modulation in graft-versus-host disease (GVHD) treatment (Fig. 2.2).

2.2.1 Tissue Regeneration

MSCs were shown to have differentiation potential into mesenchymal cells as well as endoderm and ectoderm cells. Based on this capacity, MSCs were considered as a suitable cell source for tissue regeneration from the bone, cartilage, adipose tissue, heart,

muscle, and skin. Using *in vitro* assays, MSCs have been successfully differentiated into osteoblasts (Castren et al. 2015; Glueck et al. 2015; Wang et al. 2015), chondroblasts (Ibrahim et al. 2015; Moghadam et al. 2014; Pustlauk et al. 2015), adipocytes (Li et al. 2015b; Mohammadi et al. 2015), neurons (Bagher et al. 2015; Kim et al. 2015; Nan et al. 2015), insulin-producing cells (Allahverdi et al. 2015; Balici et al. 2016; Ngoc et al. 2011; Van Pham et al. 2014), skeletal muscle (Xu et al. 2015), endothelial progenitor cells (Ikhapoh et al. 2015), cardiac progenitor cells (Li et al. 2015a; Pham et al. 2014; Yang et al. 2015c), and hepatocytes (Han et al. 2015; Sawitza et al. 2015; Ye et al. 2015).

Animal models showed that transplanted MSCs could differentiate *in vivo* into functional cells at injected sites and contribute to recovering tissue functions. In the minipig model with injured cartilage, Ha et al. (2015) showed that injected human umbilical cord blood-derived MSCs (UC-MSCs) could differentiate and regenerate the cartilage (Ha et al. 2015). Similarly, MSCs can also successfully differentiate into functional insulin-producing cells *in vivo* in diabetic mice (Yang et al. 2015b), hepatic cells (Hu and Li 2015; Zhong et al. 2015), and neurons (Taran et al. 2014). In animal models, MSCs from the bone marrow, umbilical cord blood, umbilical cord, and peripheral blood have been successfully used to treat several diseases, such as injured cartilage (Punwar and Khan 2011; Song et al. 2014), osteoarthritis (Ozeki et al. 2015; Wolfstadt et al. 2015; Xia et al. 2015), myocardial infarction (MI) (Chen et al. 2015), cornea damage (Guo et al. 2006; Ma et al. 2006), wound healing (Li et al. 2015d; Pelizzo et al. 2015), brain and spinal cord injury (Mannoji et al. 2014; Wu et al. 2015), lung failure (Liu et al. 2014a; Matthey et al. 2010), liver cirrhosis (Tang et al. 2015; Yang et al. 2015a), bone healing (Dehghan et al. 2015; Li et al. 2015c), and diabetes mellitus (DM) (Hao et al. 2013; Kong et al. 2014; Lian et al. 2014; Yaochite et al. 2015).

Based on these studies, MSCs have been clinically applied in disease treatment, especially for tissue injury and degenerative medicine. One popular application of MSCs in degenerative disease is in osteoarthritis as well as injured cartilage. Bornes et al. (2014) showed that MSC transplantation shows positive functional outcomes at 12–48 months postimplantation (Bornes et al. 2014). The first reported use of MSCs to repair cartilage damage in humans was conducted by Wakitani et al. in 1998 (Wakitani et al. 2004). To date, approximately 15 publications have reported the application of MSCs in cartilage regeneration (Bornes et al. 2014). The first MSC-based product (allogeneic umbilical cord blood MSC or CARTISTEM) was approved to treat injured cartilage in Korea in 2014. MSCs have also been clinically used in the treatment of wound healing (Falanga et al. 2007; Rasulov et al. 2005; Ravari et al. 2011; Vojtassak et al. 2006).

2.2.2 Immune Modulation

In comparison to other stem cells, MSCs exhibit a powerful capacity of regulating immune responses. Many studies showed that MSCs could regulate immune responses both *in vitro* and *in vivo*. The effects of MSCs on immune cells are summarized in Tables 2.2 and 2.3. MSCs can affect all kinds of immune cells including

Table 2.2 Immunomodulatory effects of MSCs on immune cells

Immune cell type	MSCs' effects
T lymphocyte	Suppress T-cell proliferation induced by cellular or nonspecific mitogenic stimuli (Di Nicola et al. 2002)
	Alter the cytokine secretion profile of naive and effector T cells (Aggarwal and Pittenger 2005)
	Promote the expansion and function of Treg cells (English et al. 2009)
B lymphocyte	Inhibit proliferation of B lymphocyte (Augello et al. 2005)
	Affect the chemotactic properties of B cells (Corcione et al. 2006)
	Suppress B-cell terminal differentiation (Asari et al. 2009)
NK cell	Alter the phenotype of NK cells and suppress proliferation, cytokine secretion, and cytotoxicity against HLA class I-expressing targets (Sotiropoulou et al. 2006; Spaggiari et al. 2006)
Dendritic cells (DCs)	Influence differentiation, maturation, and function of monocyte-derived dendritic cells (Zhang et al. 2004)
	Suppress dendritic cell migration, maturation, and antigen presentation (Chen et al. 2007)
	Induce mature DCs into a novel Jagged-2-dependent regulatory DC population (Zhang et al. 2009)

Table 2.3 Important bioactive molecules secreted by MSCs and their functions

Bioactive molecules	Functions
Prostaglandin E2 (PGE2)	Antiproliferative mediators (Bouffi et al. 2010)
	Anti-inflammation (Foraker et al. 2011)
Interleukin-10(IL-10)	Anti-inflammatory (Nemeth et al. 2009)
Transforming growth factor β -1 (TGF β 1), hepatocyte growth factor (HGF)	Suppress T-lymphocyte proliferation (Di Nicola et al. 2002)
Interleukin-1 receptor antagonist	Anti-inflammatory (Ortiz et al. 2007)
Human leukocyte antigen G isoform (HLA-G5)	Antiproliferative for naive T cells (Selmani et al. 2008)
LL-37	Antimicrobial peptide and reduce inflammation (Krasnodembskaya et al. 2010)
Angiopoietin-1	Restore epithelial protein permeability (Fang et al. 2010)
MMP3, MMP9	Mediating neovascularization (Kim et al. 2007)
Keratinocyte growth factor	Alveolar epithelial fluid transport (Lee et al. 2009)
Endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), placental growth factor (PlGF), and monocyte chemoattractant protein-1 (MCP-1)	Enhance proliferation of endothelial cells and smooth muscle cells (Kinnaird et al. 2004a, b)

T lymphocytes (Aggarwal and Pittenger 2005; Di Nicola et al. 2002; English et al. 2009), B lymphocytes (Asari et al. 2009; Augello et al. 2005; Corcione et al. 2006), natural killer cells (Sotiropoulou et al. 2006; Spaggiari et al. 2006), and dendritic cells (DCs) (Chen et al. 2007; Zhang et al. 2004). MSCs have thus been successfully applied in both preclinical and clinical treatments for some immune disorder-related diseases. For example, MSCs have been used to treat GVHD in patients transplanted with hematopoietic stem cells (Introna and Rambaldi 2015; von Dalowski et al. 2016; Zhao et al. 2015a), systemic lupus erythematosus (Gu et al. 2014; Wang et al. 2014a; Yan et al. 2013), Crohn's disease (Ciccocioppo et al. 2015; Liew et al. 2014), multiple system atrophy (Lee et al. 2012; Sunwoo et al. 2014), multiple sclerosis (Dulamea 2015; Gharibi et al. 2015), and amyotrophic lateral sclerosis (Hajivalili et al. 2016; Lewis and Suzuki 2014; Rushkevich et al. 2015). An allogeneic MSC-based product was approved as drug for GVHD treatment in Canada in 2015 (Prochymal, which is produced by Osiris Therapeutics). This represents the first approved stem cell drug.

2.3 Clinical Applications of MSCs

2.3.1 *Approved MSC-Based Products*

For the past 5 years, MSCs have been widely used in clinical applications mainly through two main approaches: approved MSC-based products and clinical trials. To date, approximately nine MSC-based products have been approved by several countries for the treatment of different diseases such as degenerative arthritis, post-acute MI, and GVHD (Table 2.4, Fig. 2.3). These products have been used in autologous and allogeneous transplantation in several countries and have significantly contributed to the growth of MSC clinical applications.

CARTISTEM[®], a combination of human UC-MSCs and sodium hyaluronate, is intended to be used as a single-dose therapeutic agent for cartilage regeneration in humans with cartilage defects of the knee as a result of aging, trauma, or degenerative diseases.

CardioRel[®] is an autologous product designed for early or planned intervention in patients of MI providing mononuclear and mesenchymal stem cells for cardiac regeneration.

Trinity[®] Evolution[™] is an allograft of cancellous bone containing viable adult stem cells and osteoprogenitor cells within the matrix and a demineralized bone component. Trinity Evolution offers an ideal alternative to autograft and other bone grafting options (without their drawbacks).

Osteocel[®] Plus is an allograft cellular bone matrix that retains its native bone-forming cells, including MSCs and osteoprogenitors. Osteocel[®] Plus is intended for the repair, replacement, and reconstruction of skeletal defects.

Hearticellgram[®]-AMI are bone marrow-derived MSCs (BM-MSCs) used to treat acute MI through intracoronary injection. This study assessed the safety and efficacy of intracoronary autologous transplantation of BM-MSCs in patients with

Table 2.4 Allogeneic mesenchymal stem cell-based products approved by several countries

Names of products	Components	For diseases	Kind of transplantation	Company	Country
CARTISTEM	MSCs from umbilical cord blood	Degenerative arthritis	Allo	Medipost	Korea
MPC	Mesenchymal precursor cells	N/A	Allo	Mesoblast	Australia
Cupistem	MSC from adipose tissue	Anal fistula (Crohn's disease)	Auto	Anterogen	South Korea
Prochymal	Mesenchymal stem cells from bone marrow	GVHD	Allo	Osiris Therapeutics	Canada
AlloStem	Bone matrix+BM-MSC	Orthopedics	Allo	AlloSource	USA
Hearticellgram-AMI	BM-MSC	Post-acute myocardial infarction	Auto	FCB Pharmicell	South Korea
Osteocel Plus	BM-MSC	Orthopedics	Allo	NuVasive	USA
Trinity Evolution	Bone matrix with MSC	Orthopedics	Allo	Orthofix	USA
CardioRel	BM-MNC/ MSC	Post-acute myocardial infarction	Auto	Reliance Life Science	India



Fig. 2.3 Some approved MSC-based products in some countries. (a) CARTISTEM; (b) Trinity Evolution; (c) Osteocel; (d) Prochymal

acute MI. There were no adverse reactions or major cardiac events. There was an improvement in left ventricular (LV) ejection fraction, already evident 6 h after treatment, in acute myocardial function patients who underwent percutaneous transluminal coronary angiography within 72 h of chest pain onset.

AlloStem is partially demineralized allograft bone combined with adipose-derived MSCs (AD-MSCs). Suitable for general bone grafting applications, AlloStem is similar to autograft bone because it provides the three key properties necessary for bone formation: osteoconductive (partially demineralized allograft bone, the foundation for the AlloStem tissue, provides a natural scaffold for new bone formation), osteoinductive (naturally occurring growth factors present in allograft bone have been shown to encourage osteogenic activity), and osteogenic (AlloStem contains adult MSCs that naturally adhere to the bone substrate and may contribute to the formation of new bone).

Prochymal is the first stem cell therapy approved for use in Canada. It is also the first therapy approved in Canada for acute GVHD. It is an allogeneic stem therapy based on MSCs derived from the bone marrow of adult donors. MSCs are purified from the marrow and cultured and packaged, with up to 10,000 doses derived from a single donor. The doses are stored frozen until needed.

2.3.2 Clinical Trials of MSC-Based Therapy

In addition to approved MSC-based products, MSCs have been used in disease treatment through clinical trials. According to clinicaltrials.gov, approximately 542 registered clinical trials have used MSCs for treatment. The first clinical trial using in vitro expanded MSCs was performed in 1995, in which 15 patients were treated with autologous stem cells (Lazarus et al. 1995). According to clinicaltrials.gov, almost all of the current trials are in phase I, phase II, or phase I/II, and some of these trials are in phase II or phase II/III (Fig. 2.4, Table 2.5).

2.3.2.1 MSCs for Osteoarthritis

MSCs easily differentiate into osteoblasts as well as chondroblasts, and therefore they can be rapidly applied in treating several diseases related to bone and cartilage degeneration. MSCs from various sources have been clinically used in bone and cartilage regeneration (Table 2.6).

Autologous MSCs from bone marrow were used in osteoarthritis with good results (Orozco et al. 2013). Autologous in vitro expanded MSCs were also transplanted in cartilage defects (Wong et al. 2013). Allogeneic expanded MSCs from bone marrow were used to treat chronic knee. Vega et al. (2015) showed that allogeneic MSC therapy is simple, without requirement for surgery, and significantly improves cartilage quality (Vega et al. 2015). ADSCs are also used in cartilage




Fig. 2.4 Clinical trials using mesenchymal stem cells

Table 2.5 MSC-based clinical trials in a completed status

Pathology	Clinical status completed						
	Phase I	Phase I/II	Phase II	Phase II/III	Phase III	Phase IV	ND
Overall							
Hematological disease	1	2	1	0	0	0	0
GVHD	0	4	2	0	1	0	0
Diabetes	1	1	0	0	0	0	1
Liver disease	0	3	0	0	0	0	0
Kidney disease	0	0	0	0	0	0	1
Lung disease	3	0	1	0	0	0	0
Cardiovascular disease	2	11	4	1	0	0	1
Bone and cartilage disease	12	8	3	1	2	0	3
Neurological disease	9	8	2	0	0	0	1
Crohn's disease	0	1	1	1	0	0	1
Lupus erythematosus	0	0	0	0	0	0	0
Other	3	2	1	0	11	1	2
Overall	31	40	15	3	4	1	10

regeneration. Autologous ADSCs have been successfully applied in osteoarthritis treatment. Stromal vascular fraction as non-expanded ADSCs was injected to improve knee osteoarthritis for several years (Bui et al. 2014; Koh et al. 2013; Pak 2011). Almost all studies have shown that ADSC transplantation is safe, with no treatment-related adverse events. Intra-articular injection of ADSCs into the osteoarthritic knee improved function and pain of the knee joint and reduced cartilage

Table 2.6 Clinical trials using MSCs for intra-articular injection of cells

Study name; clinicaltrials.gov identifier	Cell type and source	Indication	Study phase; design
Articular Cartilage Resurfacing With Mesenchymal Stem Cells In Osteoarthritis Of Knee Joint; NCT01207661	MSC, autologous (source unspecified)	Knee OA	Phase I; open label
Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis; NCT01227694	MSC, autologous, bone marrow derived	Knee OA	Phase I/II; open label
Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Ankle Joint Osteoarthritis; NCT01436058	MSC, autologous, bone marrow derived	Ankle joint OA	Phase I; open label
Stem Cell Transplantation for the Treatment of Knee Osteoarthritis; NCT00550524	MSC, autologous, bone marrow derived	Knee OA	Phase I; open label
Intra-Articular Autologous Bone Marrow Mesenchymal Stem Cells Transplantation to Treat Mild to Moderate Osteoarthritis; NCT01459640	MSC, autologous, bone marrow derived	Mild-to-moderate knee OA	Phase II; open label, active comparator: hyaluronic acid
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Osteoarthritis; NCT01152125	MSC, autologous, bone marrow derived	OA, KLG III–IV	Phase I/II; open label
Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells (KDD&MSV); NCT01183728	MSC, autologous, bone marrow derived	Knee OA, KLG II–IV	Phase I/II; open label
Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint; NCT01499056	MSC, autologous, bone marrow derived	Hip OA	Phase I; open label
The Effects of Intra-articular Injection of Mesenchymal Stem Cells in Knee Joint Osteoarthritis; NCT01504464	MSC, autologous, bone marrow derived	Knee OA	Phase II; double-blind RCT
Allogeneic Mesenchymal Stem Cells in Osteoarthritis; NCT01453738	MSC, allogeneic, source unspecified	Knee OA	Phase II; double-blind RCT

(continued)

Table 2.6 (continued)

Study name; clinicaltrials.gov identifier	Cell type and source	Indication	Study phase; design
Allogeneic Mesenchymal Stem Cells for Osteoarthritis; NCT01448434	MSC, allogeneic, source unspecified	Knee OA	Phase II; double-blind RCT
Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (MSV_allo); NCT01586312	MSC, allogeneic, bone marrow derived	Knee OA	Phase II; double-blind RCT, active comparator: hyaluronic acid
A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy; NCT00225095	MSC, allogeneic, source unspecified	Meniscectomy	Phase I/II; double-blind; randomized
Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy; NCT00702741	MSC, allogeneic, source unspecified	Partial medial meniscectomy	Phase II; double-blind RCT
Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction; NCT01088191	MSC, allogeneic, source unspecified	ACL reconstruction	Phase I/II; double-blind RCT, active control: hyaluronan
Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patients With Degenerative Arthritis; NCT01300598	MSC, autologous, adipose tissue derived	Knee OA	Phase I/II; open label
ADIPOA - Clinical Study; NCT01585857	MSC, autologous, adipose tissue derived	Knee OA, moderate or severe	Phase I; open label
Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis; NCT01739504	MSC, autologous, adipose tissue derived	OA	Phase I/II; open label
Outcomes Data of Bone Marrow Stem Cells to Treat Hip and Knee Osteoarthritis; NCT01601951	Bone marrow concentrate, autologous	Hip and knee OA	Phase unspecified; prospective, observational
Peripheral Blood-derived Stem Cell Trial on Damaged Knee Cartilage (PBSC); NCT01076673	Peripheral blood stem cells (identity unspecified)	Damaged articular cartilage	Phase unspecified; open label

(continued)

Table 2.6 (continued)

Study name; clinicaltrials.gov identifier	Cell type and source	Indication	Study phase; design
Allogeneic Mesenchymal Stem Cells in Osteoarthritis; NCT01453738	MSC, source unspecified, allogeneic	Knee OA, KLG II–III	Phase II; double blind
Autologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis; NCT01809769	Mesenchymal progenitor cells, autologous, adipose tissue derived	Knee OA	Phase I/II; double blind
Autologous Bone Marrow Mesenchymal Stem Cells Transplantation for Articular Cartilage Defects Repair; NCT01895413	MSC, bone marrow, autologous	Knee OA	Phase I/II; open label
Transplantation of Bone Marrow Derived mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis by <i>(sic)</i> ; NCT01873625	MSC, bone marrow, not stated whether autologous or allogeneic	Knee OA	Phase II/III; randomized, open label
Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction; NCT01088191	MSC, source unspecified	Knee, ACL injury	Phase I/II; double-blind RCT
Autologous Adipose Stem Cells and Platelet Rich Plasma Therapy for Patients With Knee Osteoarthritis; NCT02142842	SVFs (from autologous adipose tissue)	Knee, OA	Phase I/II; randomized, open label
Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis; NCT02237846	MSCs from umbilical cord (allogenic)	Knee, OA	Phase I/II

defects by regeneration of hyaline-like articular cartilage (Jo et al. 2014). Intra-articular autologous activated peripheral blood stem cells also improved quality of life and regenerated articular cartilage in early osteoarthritic knee disease (Saw et al. 2011, 2013; Turajane et al. 2013).

2.3.2.2 Cardiovascular Diseases

Today, more than 40 clinical trials are listed with a majority of bone marrow, Wharton's jelly, and adipose stem cells (Chen et al. 2004; Gee et al. 2010; Hare et al. 2009; Trachtenberg et al. 2011). Both autologous and allogeneic MSCs have been used to treat MI. In 2012, Hare et al. (2012) compared allogeneic vs. autologous BM-MSCs delivered by transendocardial injection in patients with ischemic cardiomyopathy. The authors showed that there was no difference between allogeneic and autologous BM-MSC injection, and MSC injection favorably affected patient functional capacity, quality of life, and ventricular remodeling (Hare et al. 2012). Efficiency of MSCs or mononuclear cells (MNCs) derived from bone marrow was also compared in a recent study (Heldman et al. 2014). Although both MSCs and MNCs from bone marrow were safe by transendocardial injection in ischemic cardiomyopathy patients, improvements such as the 6-min walk distance score, infarct size as a percentage of LV mass, and regional myocardial function as peak Eulerian circumferential strain at the site of injection were only improved in MSC-injected patients (Heldman et al. 2014). Gao et al. (2015) intracoronary infused Wharton's jelly-derived MSCs (WJMSCs) to treat acute MI. After 18 months of follow-up, the absolute decreases in LV end-systolic volumes and end-diastolic volumes at 18 months in the WJMSC group were significantly greater than those in the placebo group (Gao et al. 2015). In another randomized placebo-controlled clinical trial, Musialek et al. (2015) showed that allogeneic transplantation of WJMSCs is safe and effective in MI patients (Musialek et al. 2015). However, the efficiency of treatment based on MSCs differs based on the age of patients. By transendocardial injection of expanded MSCs, Golpanian et al. (2015) showed that MSC injection improved the 6-min walk distance and quality of life using the Minnesota Living with Heart Failure Questionnaire score and reduces MI size in younger patients (younger than 60 years old); in older patients, these scores were not improved (Golpanian et al. 2015).

Other diseases related to cardiovascular diseases, especially hind limb ischemia, were studied for treatment with MSC injection. ADSCs were collected and expanded *ex vivo* to treat non-revascularizable critical limb ischemia (Bura et al. 2014). ADSCs were intramuscularly injected into the ischemic leg of patients; no complications were observed, transcutaneous oxygen pressure tended to increase in most patients, and ulcer evolution and wound healing were improved (Bura et al. 2014). Allogeneic MSCs also can improve critical limb ischemia (Gupta et al. 2013). However, different than MSCs, BM-MNCs injection was insufficient to treat critical lower limb ischemia (Moazzami et al. 2014).

2.3.2.3 MSCs for Chronic Inflammatory and Autoimmune Diseases

MSCs have a strong capacity of immune modulation that affects all kinds of immune cells. Several clinical studies have examined MSCs in refractory and severe systemic lupus erythematosus treatment. Some results showed that MSC transplantation

resulted in the induction of clinical remission and improvements in serological markers of organ dysfunction (Liang et al. 2010; Sun et al. 2009; Wang et al. 2013a). MSCs have also been used in treatment of Crohn's disease, which is a chronic inflammatory disorder of the gastrointestinal tract. Crohn's disease is currently treated by steroids, immunosuppressive agents, or anti-TNF therapy; however, the efficiency of these therapies is low. MSCs from various sources, such as the bone marrow, adipose tissue, and umbilical cord of both autologous and allogeneic forms, were tested to treat Crohn's disease. Autologous BM-MSCs were safe and beneficial in refractory fistulizing Crohn's disease (Ciccocioppo et al. 2011; Duijvestein et al. 2010). Molendijk et al. (2015) showed that local administration of allogeneic BM-MSCs was not associated with severe adverse events in patients with perianal fistulizing Crohn's disease and promoted healing of perianal fistulas (Molendijk et al. 2015). These results were consistent with the study by Forbes et al., in which administration of allogeneic MSCs reduced CDAI and CDEIS scores in patients (Forbes et al. 2014).

2.3.2.4 MSCs for Liver, Lung, and Kidney Disease

The numbers of MSC-based treatments for liver, lung, and kidney diseases have increased over the past several years. The lungs are susceptible to edema and endothelial permeability caused by traumatic injury and represent good targets for MSC-based cell therapy. Three kinds of pulmonary diseases are clinically treated by MSCs, including idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and severe acute respiratory distress syndrome (ARDS). Recent clinical trials have clearly assessed the safety and feasibility of MSCs for the treatment of IPF patients. Both MSCs from the placenta (Chambers et al. 2014) and adipose tissue (Tzouveleakis et al. 2013) were used to treat IPF. The first clinical study of MSC transplantation for COPD was performed in 2013 (Weiss et al. 2013). In this report, Weiss et al. (2013) used in vitro expanded allogeneic MSCs from bone marrow with good results, showing a significant decrease in levels of circulating C-reactive protein in patients treated with MSCs (Weiss et al. 2013). Both BM-MSCs and AD-MSCs were transplanted into ARDS patients. While the clinical results showed that this is a safe method, the disease did not significantly improve after treatment (Simonson et al. 2015; Zheng et al. 2014).

MSC transplantation also shows great promise for the treatment of impaired livers, especially advanced fibrosis. Several clinical studies have examined liver fibrosis treatment by MSC transplantation. Almost all these clinical studies (over ten studies) used BM-MSCs, while four studies used allogeneic MSCs, with three studies using UC-MSCs and one study using BM-MSCs (Shi et al. 2012; Wang et al. 2014b, 2013b; Zhang et al. 2012). Interestingly, allogeneic MSC infusion is clinically safe, without side effects, and improved liver function. Zhang et al. examined the safety and efficacy of UC-MSCs in patients affected by liver cirrhosis. The results showed significantly improved liver function in transplanted patients without side effects or complications (Zhang et al. 2012). UC-MSCs were also used to treat acute chronic liver failure patients. The results showed that UC-MSC transfusions

significantly increased the survival rates in acute chronic liver failure patients (Shi et al. 2012). In summary, these data demonstrated that MSC transfusions are safe and may serve as a novel therapeutic approach for liver diseases.

MSC transplantation is also considered as a promising therapy for kidney failure based on several results in animal models. To date, three phase I/II clinical trials have examined the use of MSCs for kidney failure treatment (Gaspari et al. 2010; Gooch et al. 2008; Togel and Westenfelder 2010). Some initial results showed that MSC infusion could prevent and treat acute renal failure patients (Togel and Westenfelder 2010). Preliminary data indicate that MSC infusion is safe and feasible and that it reduced the length of hospital stay and readmission rates by 40 % (Gooch et al. 2008; Togel and Westenfelder 2010). Gooch et al. indicated that the infusion of allogeneic MSCs seemed to prevent all complications in patients with post-cardiopulmonary bypass-induced acute kidney injury and promote kidney recovery (Gooch et al. 2008).

2.3.2.5 Diabetes Mellitus (DM)

Several clinical trials have examined the application of MSCs in T1DM patients. The first clinical trial was performed by Haller et al. (2008) to assess the safety and efficacy of using MSC-containing autologous cord blood infusion for DM in children (Haller et al. 2008). This study suggested that cord blood infusion was feasible and safe; there was an increase of peripheral regulatory T-cell level and reduced insulin requirement 6 months after cord blood infusion (Haller et al. 2008). Nevertheless, after 2 years, the therapeutic effect disappeared (Haller et al. 2011).

In another study, Hu et al. evaluated the long-term effects of injecting WJMSCs for new-onset T1DM patients (Hu et al. 2013). Treated T1DM patients had better glycemic control and increased C-peptide levels after 2 years of follow-up (Hu et al. 2013). Ten other clinical trials using MSCs for DM were registered in clinicaltrials.gov. In addition to autologous MSCs, some clinical trials used allogeneic and expanded MSCs for treatment. Prochymal was also evaluated for DM treatment. Some improvements were recorded in treated patients such as glycemic control in newly diagnosed T1DM patients (NCT00690066). Four kinds of MSCs have been used in the clinic, including MSCs from the umbilical cord blood, umbilical cord, adipose tissue, and bone marrow.

MSCs have also been used to treat T2DM. Although, the mechanism of MSCs in T2DM treatment is not yet clear, some clinical trials showed that MSC transplantation is promising. Kong et al. (2014) showed that UC-MSC transfusion was safe and well tolerated, effectively alleviated blood glucose, and increased the generation of C-peptide levels and Tregs in a subgroup of T2DM patients (Kong et al. 2014). This result was similar to another study (Liu et al. 2014b). Placenta-derived MSCs also showed huge potential for T2DM treatment. Transplanted T2DM patients had no fever, chills, liver damage, or other side effects. More importantly, renal function and cardiac function were improved after infusion (Jiang et al. 2011).

2.3.2.6 MSCs in Acute Brain Injury: Stroke

In recent years, clinical trials using MSC in stroke have increased dramatically. Since 2009, there were 22 clinical trials in phase I/II (Bang et al. 2005; De Keyser 2005; Smith and Gavins 2012). Bang et al. performed the first phase I study to assess safety of intravenous administration of 10^8 autologous MSCs in patients with severe neurological deficits due to subacute ischemic stroke. The results showed that intravenous cell infusion appeared safe and feasible. In 2010, Lee et al. transplanted MSCs in 16 patients with stroke. Some neurological recovery scores were improved in the MSC group compared with the placebo group (Lee et al. 2010). Both autologous and allogeneic MSCs have been used to treat stroke. All clinical studies showed that MSC transplantation for stroke is safe, with improvement of functional recovery such as neurological scores and size of infarct. These results suggest the potential therapeutic use for MSC in stroke management.

2.4 Safety of MSCs in Clinical Applications

Although the number of clinical applications of MSCs has increased over recent years, the safety of MSCs is still a focus for scientists and medical doctors. The highest risk for MSC transplantation is tumorigenesis *in vivo* after transplantation. Some hypothesis demonstrated tumorigenesis related to MSC characteristics and some modifications in MSCs during the *in vitro* expansion. Some studies showed that MSCs without *in vitro* expansion were safe in both preclinical and clinical applications. For this reason, in 2014, the FDA clarified minimal manipulation of cell/tissue products to be used in the clinic.

In regard to *in vitro* expanded MSC transplantation, some concerns about the genetic alterations of expanded MSCs were addressed with recent *in vitro* studies as well as several clinical trials using expanded MSCs. *In vitro* assays showed that three commonly used MSC types, including BM-MSCs, ADSCs, and UC-MSCs, maintained phenotype and genotype after extended culture. For example, Bernardo et al. showed that BM-MSCs can be cultured long-term *in vitro* without losing their morphologic, phenotypical, and functional characteristics. These cells can maintain normal karyotype after 44 weeks of culture (Bernardo et al. 2007). ADSCs also did not bypass senescence after 2 months of culture, with no evidence of transformation *in vitro* (Meza-Zepeda et al. 2008). Chen et al. reported that human UC-MSCs maintained their biological characteristics and function after long-term *in vitro* culturing and were not susceptible to malignant transformation (Chen et al. 2014). In this study, MSCs could be expanded up to the 25th passage without chromosomal changes by G-band (Chen et al. 2014).

The key obstacle of stem cell therapy is related to whether stem cells may undergo malignant transformation. Some previous studies have described spontaneous transformation of MSCs *in vitro* (Pan et al. 2014; Ren et al. 2011). However, almost all of these studies have been retracted owing to cross-contamination with cancer cells

(de la Fuente et al. 2010; Garcia et al. 2010; Rubio et al. 2005; Torsvik et al. 2010). Roemeling-van Rhijn et al. (2013) showed that ADSCs can form aneuploid cells during in vitro culture. However, they also confirmed that aneuploidy was not a predecessor of transformation or tumor formation (Roemeling-van Rhijn et al. 2013). In preclinical trials, all studies on NOD mice, NOD/SCID mice, guinea pigs, rabbits, and monkey models showed that upon the use of UC-MSCs from the master MSC bank (passage 2, P2) and culturing for an additional five passages (P7) or 11 passages (P13) with a dose of 1×10^7 /mouse or 2.10^6 or 1.10^7 cells/kg body weight for monkeys, no tumor formation was observed after 2 months (Wang et al. 2012a, b).

Based on these results, in vitro or ex vivo expanded MSCs were accepted for use in clinical trials in various diseases (Table 2.7). Almost all trials were in phase II, and some were in phase I. All trials showed that expanded MSC transplantation was safe and exhibited good effects for disease improvement. Using both methods of delivery of MSCs, including intravenous infusion and local injection, MSC transplantation was shown to be safe. Performed a meta-analysis of clinical trials examining the safety of MSC transplantation, and the results confirmed the safety of MSC transplantation. A total of 2347 citations and 36 studies were reviewed, which included a total of 1012 participants with diseases such as ischemic stroke, Crohn's disease, cardiomyopathy, MI, GVHD, and healthy volunteers. The authors showed that there was no association between acute infusional toxicity, organ system complications, infection, death, and malignancy. These authors also showed that there was no difference in safety between autologous MSC and allogeneic MSCs, between matched allogeneic MSCs and unmatched allogeneic MSCs, between non-expanded MSCs and in vitro expanded MSCs, and between fresh MSCs and cryopreserved MSCs. However, there was a significant association between MSC transplantation and transient fever.

2.5 Conclusions

MSCs have become the most frequently applied stem cell type in the clinic. To date, multiple degenerative diseases and several immune-related diseases have been clinically treated by MSC transplantation. Several sources of MSCs include MSCs from the bone marrow, adipose tissue, umbilical cord blood, umbilical cord, and placenta, both with and without in vitro expansion. With useful characteristics about immune modulation, MSCs not only autologously injected into patients but allogeneic graft also was used. After over 10 years of MSC-based treatments, all reports have shown that MSC transplantation is safe. Many reports demonstrate some improvements in disease treatment using MSCs, and several MSC-based products have been approved as stem cell drugs for diseases such as GVHD and osteoarthritis. Together this demonstrates that MSC transplantation is a safe and promising therapy for disease treatment.

Table 2.7 List of completed clinical trials using ex vivo expanded MSCs

Clinical trial no.	Source of MSCs	Serum supplement	Disease treated	Dose		Route of administration	Phase	Design	References
				No. of treatment	cells/kg BW				
NCT00395200	Au-BM	FBS	Multiple sclerosis	1–2 × 10 ⁶ cells/kg BW		Intravenous	I and II	Non-randomized, safety/efficacy study, single group assignment, Open label	Connick et al. (2012) and Connick et al. (2011)
				Single					
NCT00504803	Allo-BM	Irradiated FBS	Graft-versus-host disease	–		Intravenous	II	Non-randomized, safety/efficacy study, single group assignment, open label	Baron et al. (2010)
				Single					
NCT01087996	Au-BM	–	Ischemic cardiomyopathy	20/100/200 × 10 ⁶ cells		Transendocardial	I and II	Randomized, safety/efficacy study, parallel assignment, open label	Hare et al. (2012)
				Single					
NCT00114452	Allo-BM	–	Myocardial infarction	0.5/1.6/5 × 10 ⁶ cells/kg BW		Intravenous	I	Randomized, safety study, parallel assignment, double blind (subject, caregiver, investigator, outcomes assessor)	Hare et al. (2009)
				Single					
NCT00658073	Au-BM	–	Renal transplant rejection	1–2 × 10 ⁶ cells/kg BW		Intravenous	–	Randomized, efficacy study, parallel assignment, open label	Tan et al. (2012)
				Twice					
NCT00734396	Au-BM	FBS	Renal transplant rejection	1 × 10 ⁶ cells/kg BW		Intravenous	I and II	Non-randomized, safety/efficacy study, single group assignment, open label	Reinders et al. (2013)
				Twice					
NCT00883870	Allo-BM	–	Critical limb ischemia	2 × 10 ⁶ cells/kg BW		Intramuscular (gastrocnemius muscle)	I and II	Randomized, safety/efficacy study, parallel assignment, double blind (subject, caregiver, investigator)	Gupta et al. (2013)
				Single					
NCT00823316	Allo-UCB	FBS	Graft rejection and graft-versus-host disease	1–5 × 10 ⁶ cells/kg BW		Intravenous	I and II	Randomized, safety/efficacy study, parallel assignment, open label	Lee et al. (2013)
				Single					
NCT00911365	Au-BM	FBS	Multiple system atrophy	40 × 10 ⁶ cells		Intra-arterial (one time)	II	Randomized, parallel assignment, single blind (subject)	Lee et al. (2012)
				Multiple		Intravenous (three times)			
NCT01274975	Au-AD	FBS	Spinal cord injury	400 × 10 ⁶ cells		Intravenous	I	Randomized, safety study, single group assignment, open label	Ra et al. (2011)
				Single					

NCT00683722	Allo-BM	–	Coronary obstructive pulmonary disorder	100×10 ⁶ cells Multiple	Intravenous	II	Randomized, safety/efficacy study, parallel assignment, double blind (subject, caregiver, investigator, outcome assessor)	Weiss et al. (2013)
NCT00956891	Auto-BM	FBS	Liver failure	≈100×10 ⁶ cells Single	Hepatic artery	–	Case control, retrospective	Peng et al. (2011)
NCT00187018	Allo-BM	FBS	Osteogenesis imperfecta	0.68–2.75×10 ³ cells/kg BW Single	Intravenous	–	Non-randomized, safety/efficacy study, single group assignment, open label	Otsuru et al. (2012)
NCT00816803	Auto-BM	Serum-free	Spinal cord injury	2×10 ⁶ cells/kg BW Multiple	Lumbar puncture	I and II	safety/efficacy study, parallel assignment, single blind (outcomes assessor)	El-Kheir et al. (2014)
	Allo-UC		Severe systolic heart failure		Injected into left coronary artery	I and II	Improve cardiac remodeling and cardiac function and reduce the mortality rate	Zhao et al. (2015b)
	Allo-WJ	FBS	Acute myocardial infarction	30×10 ⁶ WJMSCs	IRA using a cell-delivery perfusion catheter	I	Safety	Musialek et al. (2015)
NCT01218464	Allo-UC	FBS	Acute-on-chronic liver failure	0.5×10 ⁶ UC-MSCs, three times at 4 weeks intervals	Intravenous	I and II	Serum total bilirubin and alanine aminotransferase levels were significantly decreased UC-MSC transfusions are safe	Shi et al. (2012)
NCT01662973	Allo-UC		Primary biliary cirrhosis	0.5×10 ⁶ cells/kg body weight	Intravenous	I and II	UC-MSC transfusion is feasible and well tolerated in patients with PBC who respond only partially to UDCA treatment	Wang et al. (2013b)
	Allo-AD-MSC		Lateral epicondylitis	10 ⁶ –10 ⁷ /patient	Local injection	I and II	Allo-ASC therapy was thus safe and effective in improving elbow pain, performance, and structural defects for 52 weeks	Lee et al. (2015)
NCT00260338	Auto-BM-MSC		Myocardial ischemia		Intramyocardial injections	I and II	Not only improve symptoms but also slow down disease progression	Mathiasen et al. (2013)
NCT01392105	Auto-BM-MSC	FBS	Acute myocardial infarction	7.2±0.90×10 ⁷ cells	Intracoronary injection	II/III	Tolerable and safe with modest improvement in LVEF at 6-month follow-up by SPECT	Lee et al. (2014)

(continued)

References

- Ab Kadir R, Zainal Ariffin SH, Megat Abdul Wahab R, Kermani S, Senafi S (2012) Characterization of mononucleated human peripheral blood cells. *Scientific World Journal* 2012:843843
- Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 105:1815–1822
- Allahverdi A, Abroun S, Jafarian A, Soleimani M, Taghikhani M, Eskandari F (2015) Differentiation of human mesenchymal stem cells into insulin producing cells by using a lentiviral vector carrying PDX1. *Cell J* 17:231–242
- Asari S, Itakura S, Ferreri K, Liu CP, Kuroda Y, Kandeel F, Mullen Y (2009) Mesenchymal stem cells suppress B-cell terminal differentiation. *Exp Hematol* 37:604–615
- Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G (2005) Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. *Eur J Immunol* 35:1482–1490
- Bagher Z, Ebrahimi-Barough S, Azami M, Mirzadeh H, Soleimani M, Ai J, Nourani MR, Joghataei MT (2015) Induction of human umbilical Wharton's jelly-derived mesenchymal stem cells toward motor neuron-like cells. *In Vitro Cell Dev Biol Anim* 51(9):987–994
- Balici S, Susman S, Rusu D, Nicula GZ, Soritau O, Rusu M, Biris AS, Matei H (2016) Differentiation of stem cells into insulin-producing cells under the influence of nanostructural polyoxometalates. *J Appl Toxicol* 36(3):373–384
- Bang OY, Lee JS, Lee PH, Lee G (2005) Autologous mesenchymal stem cell transplantation in stroke patients. *Ann Neurol* 57:874–882
- Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafroui K, Lejeune M, Gothot A et al (2010) Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. *Biol Blood Marrow Transplant* 16:838–847
- Bartsch G, Yoo JJ, De Coppi P, Siddiqui MM, Schuch G, Pohl HG, Fuhr J, Perin L, Soker S, Atala A (2005) Propagation, expansion, and multilineage differentiation of human somatic stem cells from dermal progenitors. *Stem Cells Dev* 14:337–348
- Becker AJ, Mc CE, Till JE (1963) Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. *Nature* 197:452–454
- Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG et al (2007) Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. *Cancer Res* 67:9142–9149
- Bornes TD, Adesida AB, Jomha NM (2014) Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review. *Arthritis Res Ther* 16:432
- Bouffi C, Bony C, Courties G, Jorgensen C, Noel D (2010) IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. *PLoS One* 5, e14247
- Bui KH-T, Duong TD, Nguyen NT, Nguyen TD, Le VT, Mai VT, Phan NL-C, Le DM, Phan NK, Van Pham P (2014) Symptomatic knee osteoarthritis treatment using autologous adipose derived stem cells and platelet-rich plasma: a clinical study. *Biomed Res Ther* 1:2–8
- Bura A, Planat-Benard V, Bourin P, Silvestre JS, Gross F, Grolleau JL, Saint-Lebesse B, Peyrafitte JA, Fleury S, Gadelorge M et al (2014) Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. *Cytotherapy* 16:245–257
- Cai J, Li W, Su H, Qin D, Yang J, Zhu F, Xu J, He W, Guo X, Labuda K et al (2010) Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. *J Biol Chem* 285:11227–11234
- Castrechini NM, Murthi P, Qin S, Kusuma GD, Wilton L, Abumaree M, Gronthos S, Zannettino A, Gude NM, Brennecke SP et al (2012) Decidua parietalis-derived mesenchymal stromal cells reside in a vascular niche within the choriodecidua. *Reprod Sci* 19:1302–1314

- Castren E, Sillat T, Oja S, Noro A, Laitinen A, Kontinen YT, Lehenkari P, Hukkanen M, Korhonen M (2015) Osteogenic differentiation of mesenchymal stromal cells in two-dimensional and three-dimensional cultures without animal serum. *Stem Cell Res Ther* 6:167
- Chambers DC, Enever D, Ilic N, Sparks L, Whitelaw K, Ayres J, Yerkovich ST, Khalil D, Atkinson KM, Hopkins PM (2014) A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. *Respirology* 19:1013–1018
- Chen G, Yue A, Ruan Z, Yin Y, Wang R, Ren Y, Zhu L (2014) Human umbilical cord-derived mesenchymal stem cells do not undergo malignant transformation during long-term culturing in serum-free medium. *PLoS One* 9, e98565
- Chen L, Zhang W, Yue H, Han Q, Chen B, Shi M, Li J, Li B, You S, Shi Y et al (2007) Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. *Stem Cells Dev* 16:719–731
- Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S et al (2004) Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. *Am J Cardiol* 94:92–95
- Chen YL, Sun CK, Tsai TH, Chang LT, Leu S, Zhen YY, Sheu JJ, Chua S, Yeh KH, Lu HI et al (2015) Adipose-derived mesenchymal stem cells embedded in platelet-rich fibrin scaffolds promote angiogenesis, preserve heart function, and reduce left ventricular remodeling in rat acute myocardial infarction. *Am J Transl Res* 7:781–803
- Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, Minelli A, Alvisi C, Vanoli A, Calliada F et al (2011) Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. *Gut* 60:788–798
- Ciccocioppo R, Gallia A, Sgarella A, Kruzliak P, Gobbi PG, Corazza GR (2015) Long-term follow-up of Crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells. *Mayo Clin Proc* 90:747–755
- Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ et al (2012) Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. *Lancet Neurol* 11:150–156
- Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He XL, Richardson K, Barber K, Webber DJ, Wheeler-Kingshott CA et al (2011) The mesenchymal stem cells in multiple sclerosis (MSCMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. *Trials* 12:62
- Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Rizzo M, Gualandi F, Mancardi GL, Pistoia V et al (2006) Human mesenchymal stem cells modulate B-cell functions. *Blood* 107:367–372
- De Keyser J (2005) Autologous mesenchymal stem cell transplantation in stroke patients. *Ann Neurol* 58:653–654, author reply 654–655
- de la Fuente R, Bernad A, Garcia-Castro J, Martin MC, Cigudosa JC (2010) Retraction: spontaneous human adult stem cell transformation. *Cancer Res* 70:6682
- Dehghan MM, Baghaban Eslaminejad M, Motallebizadeh N, Ashrafi Halan J, Tagiyar L, Soroori S, Nikmahzar A, Pedram M, Shahverdi A, Kazemi Mehrjerdi H et al (2015) Transplantation of autologous bone marrow mesenchymal stem cells with platelet-rich plasma accelerate distraction osteogenesis in a canine model. *Cell J* 17:243–252
- Di Nicola M, Carlo-Stella C, Magni M, Milanese M, Longoni PD, Matteucci P, Grisanti S, Gianni AM (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood* 99:3838–3843
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 8:315–317
- Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH et al (2010) Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. *Gut* 59:1662–1669

- Dulamea A (2015) Mesenchymal stem cells in multiple sclerosis—translation to clinical trials. *J Med Life* 8:24–27
- El-Kheir WA, Gabr H, Awad MR, Ghannam O, Barakat Y, Farghali HA, El Maadawi ZM, Ewes I, Sabaawy HE (2014) Autologous bone marrow-derived cell therapy combined with physical therapy induces functional improvement in chronic spinal cord injury patients. *Cell Transplant* 23:729–745
- English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP (2009) Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. *Clin Exp Immunol* 156:149–160
- Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, Shrayder D, Carson P (2007) Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. *Tissue Eng* 13:1299–1312
- Fang X, Neyrinck AP, Matthay MA, Lee JW (2010) Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. *J Biol Chem* 285:26211–26222
- Foraker JE, Oh JY, Ylostalo JH, Lee RH, Watanabe J, Prockop DJ (2011) Cross-talk between human mesenchymal stem/progenitor cells (MSCs) and rat hippocampal slices in LPS-stimulated cocultures: the MSCs are activated to secrete prostaglandin E2. *J Neurochem* 119:1052–1063
- Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, Phillips M, Herrmann RP (2014) A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. *Clin Gastroenterol Hepatol* 12:64–71
- Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Ruadkow IA (1974) Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. *Exp Hematol* 2:83–92
- Friedenstein AJ, Gorskaja JF, Kulagina NN (1976) Fibroblast precursors in normal and irradiated mouse hematopoietic organs. *Exp Hematol* 4:267–274
- Gao LR, Chen Y, Zhang NK, Yang XL, Liu HL, Wang ZG, Yan XY, Wang Y, Zhu ZM, Li TC et al (2015) Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. *BMC Med* 13:162
- Garcia S, Bernad A, Martin MC, Cigudosa JC, Garcia-Castro J, de la Fuente R (2010) Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. *Exp Cell Res* 316:1648–1650
- Gaspari F, Cravedi P, Mandala M, Perico N, de Leon FR, Stucchi N, Ferrari S, Labianca R, Remuzzi G, Ruggenti P (2010) Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. *Nephron Clin Pract* 115:c154–c160
- Gee AP, Richman S, Durett A, McKenna D, Traverse J, Henry T, Fisk D, Pepine C, Bloom J, Willerson J (2010) Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRn) experience. *Cytherapy* 12:684–691
- Gharibi T, Ahmadi M, Seyfizadeh N, Jadidi-Niaragh F, Yousefi M (2015) Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis. *Cell Immunol* 293:113–121
- Glueck M, Gardner O, Czekanska E, Alini M, Stoddart MJ, Salzman GM, Schmal H (2015) Induction of osteogenic differentiation in human mesenchymal stem cells by crosstalk with osteoblasts. *Biores Open Access* 4:121–130
- Golpanian S, El-Khorazaty J, Mendizabal A, DiFede DL, Suncion VY, Karantalis V, Fishman JE, Ghersein E, Balkan E, Hare JM (2015) Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients. *J Am Coll Cardiol* 65:125–132
- Gooch A, Doty J, Flores J, Swenson L, Toegel F, Reiss G, Lange C, Zander A, Hu Z, Poole S (2008) Initial report on a phase I clinical trial: prevention and treatment of post-operative acute

- kidney injury with allogeneic mesenchymal stem cells in patients who require on-pump cardiac surgery. *Cell Ther Transplant* 1:31–35
- Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM (2001) Surface protein characterization of human adipose tissue-derived stromal cells. *J Cell Physiol* 189:54–63
- Gu F, Wang D, Zhang H, Feng X, Gilkeson GS, Shi S, Sun L (2014) Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. *Clin Rheumatol* 33:1611–1619
- Guo T, Wang W, Zhang J, Chen X, Li BZ, Li LS (2006) Experimental study on repairing damage of corneal surface by mesenchymal stem cells transplantation. *Zhonghua Yan Ke Za Zhi* 42:246–250
- Gupta PK, Chullickana A, Parakh R, Desai S, Das A, Gottipamula S, Krishnamurthy S, Anthony N, Pherwani A, Majumdar AS (2013) A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. *J Transl Med* 11:143
- Ha CW, Park YB, Chung JY, Park YG (2015) Cartilage repair using composites of human umbilical cord blood-derived mesenchymal stem cells and hyaluronic acid hydrogel in a minipig model. *Stem Cells Transl Med* 4:1044–1051
- Hajivalili M, Pourgholi F, Kafil HS, Jadidi-Niaragh F, Yousefi M (2016) Mesenchymal stem cells in the treatment of amyotrophic lateral sclerosis. *Curr Stem Cell Res Ther* 11(1):41–50
- Haller MJ, Viener HL, Wasserfall C, Brusko T, Atkinson MA, Schatz DA (2008) Autologous umbilical cord blood infusion for type 1 diabetes. *Exp Hematol* 36:710–715
- Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Sumrall TM, Wingard JR, Theriaque DW, Shuster JJ et al (2011) Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. *Diabetes Care* 34:2567–2569
- Han SM, Coh YR, Ahn JO, Jang G, Yum SY, Kang SK, Lee HW, Youn HY (2015) Enhanced hepatogenic transdifferentiation of human adipose tissue mesenchymal stem cells by gene engineering with Oct4 and Sox2. *PLoS One* 10, e0108874
- Hao H, Liu J, Shen J, Zhao Y, Liu H, Hou Q, Tong C, Ti D, Dong L, Cheng Y et al (2013) Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. *Biochem Biophys Res Commun* 436:418–423
- Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Gershin E, Johnston PV, Brinker JA et al (2012) Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. *JAMA* 308:2369–2379
- Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS et al (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. *J Am Coll Cardiol* 54:2277–2286
- Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK et al (2014) Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. *JAMA* 311:62–73
- Hou T, Xu J, Wu X, Xie Z, Luo F, Zhang Z, Zeng L (2009) Umbilical cord Wharton's Jelly: a new potential cell source of mesenchymal stromal cells for bone tissue engineering. *Tissue Eng Part A* 15:2325–2334
- Hu C, Li L (2015) In vitro and in vivo hepatic differentiation of adult somatic stem cells and extra-embryonic stem cells for treating end stage liver diseases. *Stem Cells Int* 2015:871972
- Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, Chen Y, Zhao W, Jia Z, Yan S et al (2013) Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. *Endocr J* 60:347–357
- Huang GT, Gronthos S, Shi S (2009) Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. *J Dent Res* 88:792–806

- Ibrahim AM, Elgharabawi NM, Makhlof MM, Ibrahim OY (2015) Chondrogenic differentiation of human umbilical cord blood-derived mesenchymal stem cells in vitro. *Microsc Res Tech* 78:667–675
- Ikhapoh IA, Pelham CJ, Agrawal DK (2015) Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells. *Differentiation* 89:87–96
- In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FH, Willemze R, Fibbe WE, Kanhai HH (2003) Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. *Blood* 102:1548–1549
- Introna M, Rambaldi A (2015) Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles. *Curr Opin Organ Transplant* 20:72–78
- Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, Shao Y, Yang S, Han ZC (2011) Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. *Front Med* 5:94–100
- Jiao F, Wang J, Dong ZL, Wu MJ, Zhao TB, Li DD, Wang X (2012) Human mesenchymal stem cells derived from limb bud can differentiate into all three embryonic germ layers lineages. *Cell Reprogram* 14:324–333
- Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, Kim JE, Shim H, Shin JS, Shin IS et al (2014) Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. *Stem Cells* 32:1254–1266
- Kadar K, Kiraly M, Porcsalmy B, Molnar B, Racz GZ, Blazsek J, Kallo K, Szabo EL, Gera I, Gerber G et al (2009) Differentiation potential of stem cells from human dental origin - promise for tissue engineering. *J Physiol Pharmacol* 60(Suppl 7):167–175
- Kim H, Kim I, Choi HJ, Kim SY, Yang EG (2015) Neuron-like differentiation of mesenchymal stem cells on silicon nanowires. *Nanoscale* 7(40):17131–17138
- Kim Y, Kim H, Cho H, Bae Y, Suh K, Jung J (2007) Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. *Cell Physiol Biochem* 20:867–876
- Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE (2004a) Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. *Circ Res* 94:678–685
- Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE (2004b) Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. *Circulation* 109:1543–1549
- Kita K, Gauglitz GG, Phan TT, Herndon DN, Jeschke MG (2010) Isolation and characterization of mesenchymal stem cells from the sub-amniotic human umbilical cord lining membrane. *Stem Cells Dev* 19:491–502
- Koh YG, Jo SB, Kwon OR, Suh DS, Lee SW, Park SH, Choi YJ (2013) Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. *Arthroscopy* 29:748–755
- Kong D, Zhuang X, Wang D, Qu H, Jiang Y, Li X, Wu W, Xiao J, Liu X, Liu J et al (2014) Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. *Clin Lab* 60:1969–1976
- Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, Matthey MA (2010) Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. *Stem Cells* 28:2229–2238
- Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI (1995) Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. *Bone Marrow Transplant* 16:557–564
- Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY (2010) A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. *Stem Cells* 28:1099–1106
- Lee JW, Fang X, Gupta N, Serikov V, Matthey MA (2009) Allogeneic human mesenchymal stem cells for treatment of *E. coli* endotoxin-induced acute lung injury in the ex vivo perfused human lung. *Proc Natl Acad Sci U S A* 106:16357–16362

- Lee JW, Lee SH, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Kwon W, Hong IS, Lee K et al (2014) A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. *J Korean Med Sci* 29:23–31
- Lee PH, Lee JE, Kim HS, Song SK, Lee HS, Nam HS, Cheong JW, Jeong Y, Park HJ, Kim DJ et al (2012) A randomized trial of mesenchymal stem cells in multiple system atrophy. *Ann Neurol* 72:32–40
- Lee SH, Lee MW, Yoo KH, Kim DS, Son MH, Sung KW, Cheuh H, Choi SJ, Oh W, Yang YS et al (2013) Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. *Bone Marrow Transplant* 48:1040–1045
- Lee SY, Kim W, Lim C, Chung SG (2015) Treatment of lateral epicondylitis by using allogeneic adipose-derived mesenchymal stem cells: a pilot study. *Stem Cells* 33:2995–3005
- Lewis CM, Suzuki M (2014) Therapeutic applications of mesenchymal stem cells for amyotrophic lateral sclerosis. *Stem Cell Res Ther* 5:32
- Li J, Zhu K, Wang Y, Zheng J, Guo C, Lai H, Wang C (2015a) Combination of IGF1 gene manipulation and 5AZA treatment promotes differentiation of mesenchymal stem cells into cardiomyocyte-like cells. *Mol Med Rep* 11:815–820
- Li R, Liang L, Dou Y, Huang Z, Mo H, Wang Y, Yu B (2015b) Mechanical strain regulates osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells. *Biomed Res Int* 2015:873251
- Li S, Huang KJ, Wu JC, Hu MS, Sanyal M, Hu M, Longaker MT, Lorenz HP (2015c) Peripheral blood-derived mesenchymal stem cells: candidate cells responsible for healing critical-sized calvarial bone defects. *Stem Cells Transl Med* 4:359–368
- Li Z, Wang H, Yang B, Sun Y, Huo R (2015d) Three-dimensional graphene foams loaded with bone marrow derived mesenchymal stem cells promote skin wound healing with reduced scarring. *Mater Sci Eng C Mater Biol Appl* 57:181–188
- Lian Z, Yin X, Li H, Jia L, He X, Yan Y, Liu N, Wan K, Li X, Lin S (2014) Synergistic effect of bone marrow-derived mesenchymal stem cells and platelet-rich plasma in streptozotocin-induced diabetic rats. *Ann Dermatol* 26:1–10
- Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L (2010) Allogeneic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. *Ann Rheum Dis* 69:1423–1429
- Liew A, O'Brien T, Egan L (2014) Mesenchymal stromal cell therapy for Crohn's disease. *Dig Dis* 32(Suppl 1):50–60
- Liu F, Gao F, Li Q, Liu Z (2014a) The functional study of human umbilical cord mesenchymal stem cells harbouring angiotensin-converting enzyme 2 in rat acute lung ischemia-reperfusion injury model. *Cell Biochem Funct* 32:580–589
- Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y (2014b) A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. *Stem Cell Res Ther* 5:57
- Ma Y, Xu Y, Xiao Z, Yang W, Zhang C, Song E, Du Y, Li L (2006) Reconstruction of chemically burned rat corneal surface by bone marrow-derived human mesenchymal stem cells. *Stem Cells* 24:315–321
- Mamidi MK, Nathan KG, Singh G, Thrichelvam ST, Mohd Yusof NA, Fakharuzi NA, Zakaria Z, Bhonde R, Das AK, Majumdar AS (2012) Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation. *J Cell Biochem* 113:3153–3164
- Mannaji C, Koda M, Kamiya K, Dezawa M, Hashimoto M, Furuya T, Okawa A, Takahashi K, Yamazaki M (2014) Transplantation of human bone marrow stromal cell-derived neuroregenerative cells promotes functional recovery after spinal cord injury in mice. *Acta Neurobiol Exp (Wars)* 74:479–488
- Mathiasen AB, Haack-Sorensen M, Jorgensen E, Kastrup J (2013) Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina—final 3-year follow-up. *Int J Cardiol* 170:246–251

- Matthay MA, Goolaerts A, Howard JP, Lee JW (2010) Mesenchymal stem cells for acute lung injury: preclinical evidence. *Crit Care Med* 38:S569–S573
- Meza-Zepeda LA, Noer A, Dahl JA, Micci F, Myklebost O, Collas P (2008) High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. *J Cell Mol Med* 12:553–563
- Moazzami K, Moazzami B, Roohi A, Nedjat S, Dolmatova E (2014) Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. *Cochrane Database Syst Rev* 12, CD008347
- Moghadam FH, Tayebi T, Dehghan M, Eslami G, Nadri H, Moradi A, Vahedian-Ardakani H, Barzegar K (2014) Differentiation of bone marrow mesenchymal stem cells into chondrocytes after short term culture in alkaline medium. *Int J Hematol Oncol Stem Cell Res* 8:12–19
- Mohammadi Z, Afshari JT, Keramati MR, Alamdari DH, Ganjibakhsh M, Zarmehri AM, Jangjoo A, Sadeghian MH, Ameri MA, Moinsadeh L (2015) Differentiation of adipocytes and osteocytes from human adipose and placental mesenchymal stem cells. *Iran J Basic Med Sci* 18:259–266
- Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G, van der Woude CJ, Duijvestein M, Veenendaal RA, Zwaginga JJ et al (2015) Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn's disease. *Gastroenterology* 149:918–927 e916
- Moretti P, Hatlapatka T, Marten D, Lavrentieva A, Majore I, Hass R, Kasper C (2010) Mesenchymal stromal cells derived from human umbilical cord tissues: primitive cells with potential for clinical and tissue engineering applications. *Adv Biochem Eng Biotechnol* 123:29–54
- Morito T, Muneta T, Hara K, Ju YJ, Mochizuki T, Makino H, Umezawa A, Sekiya I (2008) Synovial fluid-derived mesenchymal stem cells increase after intra-articular ligament injury in humans. *Rheumatology (Oxford)* 47:1137–1143
- Musialek P, Mazurek A, Jarocha D, Tekieli L, Szot W, Kostkiewicz M, Banys RP, Urbanczyk M, Kadzielski A, Trystula M et al (2015) Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf 'unlimited' therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study. *Postepy Kardiologii Interwencyjnej* 11:100–107
- Nan C, Shi Y, Zhao Z, Ma S, Liu J, Yan D, Song G, Liu H (2015) Monosialotetrahexosyl ganglioside induces the differentiation of human umbilical cord-derived mesenchymal stem cells into neuron-like cells. *Int J Mol Med* 36:1057–1062
- Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM et al (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med* 15:42–49
- Ngoc PK, Phuc PV, Nhung TH, Thuy DT, Nguyet NT (2011) Improving the efficacy of type 1 diabetes therapy by transplantation of immunoisolated insulin-producing cells. *Hum Cell* 24:86–95
- Orozco L, Munar A, Soler R, Alberca M, Soler F, Huguet M, Sentis J, Sanchez A, Garcia-Sancho J (2013) Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. *Transplantation* 95:1535–1541
- Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. *Proc Natl Acad Sci U S A* 104:11002–11007
- Otsuru S, Gordon PL, Shimono K, Jethva R, Marino R, Phillips CL, Hofmann TJ, Veronesi E, Dominici M, Iwamoto M et al (2012) Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. *Blood* 120:1933–1941
- Otsuru S, Hofmann TJ, Olson TS, Dominici M, Horwitz EM (2013) Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device. *Cytherapy* 15:146–153
- Ozeki N, Muneta T, Matsuta S, Koga H, Nakagawa Y, Mizuno M, Tsuji K, Mabuchi Y, Akazawa C, Kobayashi E et al (2015) Synovial mesenchymal stem cells promote meniscus regeneration augmented by an autologous Achilles tendon graft in a rat partial meniscus defect model. *Stem Cells* 33:1927–1938

- Pak J (2011) Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series. *J Med Case Rep* 5:296
- Pan Q, Fouraschen SM, de Ruiter PE, Dinjens WN, Kwekkeboom J, Tilanus HW, van der Laan LJ (2014) Detection of spontaneous tumorigenic transformation during culture expansion of human mesenchymal stromal cells. *Exp Biol Med* (Maywood) 239:105–115
- Patki S, Kadam S, Chandra V, Bhone R (2010) Human breast milk is a rich source of multipotent mesenchymal stem cells. *Hum Cell* 23:35–40
- Pelizzo G, Avanzini MA, Icaro Cornaglia A, Osti M, Romano P, Avolio L, Maccario R, Dominici M, De Silvestri A, Andreatta E et al (2015) Mesenchymal stromal cells for cutaneous wound healing in a rabbit model: pre-clinical study applicable in the pediatric surgical setting. *J Transl Med* 13:219
- Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, Zheng YB, Gao ZL (2011) Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. *Hepatology* 54:820–828
- Pham TL, Nguyen TT, Van Bui A, Nguyen MT, Van Pham P (2014). Fetal heart extract facilitates the differentiation of human umbilical cord blood-derived mesenchymal stem cells into heart muscle precursor cells. *Cytotechnology*, doi:[10.1007/s10616-014-9812-2](https://doi.org/10.1007/s10616-014-9812-2). [Epub ahead of print]
- Punwar S, Khan WS (2011) Mesenchymal stem cells and articular cartilage repair: clinical studies and future direction. *Open Orthop J* 5(Suppl 2):296–301
- Pustlank W, Paul B, Brueggemeier S, Gelinsky M, Bernhardt A (2015) Modulation of chondrogenic differentiation of human mesenchymal stem cells in jellyfish collagen scaffolds by cell density and culture medium. *J Tissue Eng Regen Med*, doi:[10.1002/term.2065](https://doi.org/10.1002/term.2065). [Epub ahead of print]
- Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ, Choi HJ et al (2011) Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. *Stem Cells Dev* 20:1297–1308
- Rasulov MF, Vasilchenkov AV, Onishchenko NA, Krashennnikov ME, Kravchenko VI, Gorshenin TL, Pidtsan RE, Potapov IV (2005) First experience of the use bone marrow mesenchymal stem cells for the treatment of a patient with deep skin burns. *Bull Exp Biol Med* 139:141–144
- Ravari H, Hamidi-Almadari D, Salimifar M, Bonakdaran S, Parizadeh MR, Koliakos G (2011) Treatment of non-healing wounds with autologous bone marrow cells, platelets, fibrin glue and collagen matrix. *Cytotherapy* 13:705–711
- Raynaud CM, Maleki M, Lis R, Ahmed B, Al-Azwani I, Malek J, Safadi FF, Rafi A (2012) Comprehensive characterization of mesenchymal stem cells from human placenta and fetal membrane and their response to osteoactivin stimulation. *Stem Cells Int* 2012:658356
- Reinders ME, de Fijter JW, Roelofs H, Bajema IM, de Vries DK, Schaapherder AF, Claas FH, van Miert PP, Roelen DL, van Kooten C et al (2013) Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. *Stem Cells Transl Med* 2:107–111
- Ren Z, Wang J, Zhu W, Guan Y, Zou C, Chen Z, Zhang YA (2011) Spontaneous transformation of adult mesenchymal stem cells from cynomolgus macaques in vitro. *Exp Cell Res* 317:2950–2957
- Riekstina U, Muceniece R, Cakstina I, Muiznieks I, Ancans J (2008) Characterization of human skin-derived mesenchymal stem cell proliferation rate in different growth conditions. *Cytotechnology* 58:153–162
- Roemeling-van Rhijn M, de Klein A, Douben H, Pan Q, van der Laan LJ, Ijzermans JN, Betjes MG, Baan CC, Weimar W, Hoogduijn MJ (2013) Culture expansion induces non-tumorigenic aneuploidy in adipose tissue-derived mesenchymal stromal cells. *Cytotherapy* 15:1352–1361
- Rosignoli F, Caselli A, Grisendi G, Piccinno S, Burns JS, Murgia A, Veronesi E, Loschi P, Masini C, Conte P et al (2013) Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood. *Biomed Res Int* 2013:901821
- Rotter N, Oder J, Schlenke P, Lindner U, Bohrsen F, Kramer J, Rohwedel J, Huss R, Brandau S, Wollenberg B et al (2008) Isolation and characterization of adult stem cells from human salivary glands. *Stem Cells Dev* 17:509–518

- Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A (2005) Spontaneous human adult stem cell transformation. *Cancer Res* 65:3035–3039
- Rushkevich YN, Kosmacheva SM, Zabrodets GV, Ignatenko SI, Goncharova NV, Severin IN, Likhachev SA, Potapnev MP (2015) The use of autologous mesenchymal stem cells for cell therapy of patients with amyotrophic lateral sclerosis in Belarus. *Bull Exp Biol Med* 159:576–581
- Saw KY, Anz A, Merican S, Tay YG, Ragavanaidu K, Jee CS, McGuire DA (2011) Articular cartilage regeneration with autologous peripheral blood progenitor cells and hyaluronic acid after arthroscopic subchondral drilling: a report of 5 cases with histology. *Arthroscopy* 27:493–506
- Saw KY, Anz A, Siew-Yoke Jee C, Merican S, Ching-Soong Ng R, Roohi SA, Ragavanaidu K (2013) Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. *Arthroscopy* 29:684–694
- Sawitz A, Kordes C, Gotze S, Herebian D, Haussinger D (2015) Bile acids induce hepatic differentiation of mesenchymal stem cells. *Sci Rep* 5:13320
- Schuring AN, Schulte N, Kelsch R, Ropke A, Kiesel L, Gotte M (2011) Characterization of endometrial mesenchymal stem-like cells obtained by endometrial biopsy during routine diagnostics. *Fertil Steril* 95:423–426
- Seifrtova M, Havelek R, Cmielova J, Jiroutova A, Soukup T, Bruckova L, Mokry J, English D, Rezacova M (2012) The response of human ectomesenchymal dental pulp stem cells to cisplatin treatment. *Int Endod J* 45:401–412
- Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N et al (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4⁺CD25^{high}FOXP3⁺ regulatory T cells. *Stem Cells* 26:212–222
- Shi M, Zhang Z, Xu R, Lin H, Fu J, Zou Z, Zhang A, Shi J, Chen L, Lv S et al (2012) Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. *Stem Cells Transl Med* 1:725–731
- Siminovitch L, McCulloch EA, Till JE (1963) THE distribution of colony-forming cells among spleen colonies. *J Cell Physiol* 62:327–336
- Simonson OE, Mougiakakos D, Heldring N, Bassi G, Johansson HJ, Dalen M, Jitschin R, Rodin S, Corbascio M, El Andaloussi S et al (2015) In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. *Stem Cells Transl Med* 4:1199–1213
- Smith HK, Gavins FN (2012) The potential of stem cell therapy for stroke: is PISCES the sign? *FASEB J* 26:2239–2252
- Song F, Tang J, Geng R, Hu H, Zhu C, Cui W, Fan W (2014) Comparison of the efficacy of bone marrow mononuclear cells and bone mesenchymal stem cells in the treatment of osteoarthritis in a sheep model. *Int J Clin Exp Pathol* 7:1415–1426
- Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M (2006) Interactions between human mesenchymal stem cells and natural killer cells. *Stem Cells* 24:74–85
- Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L (2006) Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. *Blood* 107:1484–1490
- Stewart K, Walsh S, Screen J, Jefferiss CM, Chainey J, Jordan GR, Beresford JN (1999) Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. *J Bone Miner Res* 14:1345–1356
- Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S (2009) Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. *Stem Cells* 27:1421–1432
- Sunwoo MK, Yun HJ, Song SK, Ham JH, Hong JY, Lee JE, Lee HS, Sohn YH, Lee JM, Lee PH (2014) Mesenchymal stem cells can modulate longitudinal changes in cortical thickness and its related cognitive decline in patients with multiple system atrophy. *Front Aging Neurosci* 6:118
- Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X, Chen J, Yang S, Cai J et al (2012) Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. *JAMA* 307:1169–1177

- Tang WP, Akahoshi T, Piao JS, Narahara S, Murata M, Kawano T, Hamano N, Ikeda T, Hashizume M (2015) Splenectomy enhances the therapeutic effect of adipose tissue-derived mesenchymal stem cell infusion on cirrhosis rats. *Liver Int* 36(8):1151–9
- Taran R, Mamidi MK, Singh G, Dutta S, Parhar IS, John JP, Bhonde R, Pal R, Das AK (2014) In vitro and in vivo neurogenic potential of mesenchymal stem cells isolated from different sources. *J Biosci* 39:157–169
- Togel FE, Westenfelder C (2010) Mesenchymal stem cells: a new therapeutic tool for AKI. *Nat Rev Nephrol* 6:179–183
- Torsvik A, Rosland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lonning PE, Primom M, Sobala E, Tonn JC et al (2010) Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track—letter. *Cancer Res* 70:6393–6396
- Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R, Mendizabal A et al (2011) Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. *Am Heart J* 161:487–493
- Tsai MS, Lee JL, Chang YJ, Hwang SM (2004) Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. *Hum Reprod* 19:1450–1456
- Turajane T, Chaweewannakorn U, Larbpaiboonpong V, Aojanepong J, Thitiset T, Honsawek S, Fongsarun J, Papadopoulos KI (2013) Combination of intra-articular autologous activated peripheral blood stem cells with growth factor addition/preservation and hyaluronic acid in conjunction with arthroscopic microdrilling mesenchymal cell stimulation Improves quality of life and regenerates articular cartilage in early osteoarthritic knee disease. *J Med Assoc Thai* 96:580–588
- Tzouveleakis A, Paspaliaris V, Koliakos G, Ntoliou P, Bouros E, Oikonomou A, Zissimopoulos A, Bousios N, Dardzinski B, Gritzalis D et al (2013) A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. *J Transl Med* 11:171
- Van Pham P, Thi-My Nguyen P, Thai-Quynh Nguyen A, Minh Pham V, Nguyen-Tu Bui A, Thi-Tung Dang L, Gia Nguyen K, Kim Phan N (2014) Improved differentiation of umbilical cord blood-derived mesenchymal stem cells into insulin-producing cells by PDX-1 mRNA transfection. *Differentiation* 87:200–208
- Vega A, Martin-Ferrero MA, Del Canto F, Alberca M, Garcia V, Munar A, Orozco L, Soler R, Fuertes JJ, Huguet M et al (2015) Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. *Transplantation* 99:1681–1690
- Vojtassak J, Danisovic L, Kubes M, Bakos D, Jarabek L, Ulicna M, Blasko M (2006) Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. *Neuro Endocrinol Lett* 27(Suppl 2):134–137
- von Dalowski F, Kramer M, Wermke M, Wehner R, Rollig C, Alakel N, Stolzel F, Parmentier S, Sockel K, Krech M et al (2016) Mesenchymal stromal cells for treatment of acute steroid-refractory GvHD: clinical responses and long-term outcome. *Stem Cells* 34(2):357–366
- Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S (2004) Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. *Cell Transplant* 13:595–600
- Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, Hu X, Jiang S, Shi S, Sun L (2014a) Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. *Arthritis Res Ther* 16:R79
- Wang D, Zhang H, Liang J, Li X, Feng X, Wang H, Hua B, Liu B, Lu L, Gilkeson GS et al (2013a) Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. *Cell Transplant* 22:2267–2277
- Wang L, Han Q, Chen H, Wang K, Shan GL, Kong F, Yang YJ, Li YZ, Zhang X, Dong F et al (2014b) Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. *Stem Cells Dev* 23:2482–2489

- Wang L, Li J, Liu H, Li Y, Fu J, Sun Y, Xu R, Lin H, Wang S, Lv S et al (2013b) Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. *J Gastroenterol Hepatol* 28(Suppl 1):85–92
- Wang L, Li ZY, Wang YP, Wu ZH, Yu B (2015) Dynamic expression profiles of marker genes in osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. *Chin Med Sci J* 30:108–113
- Wang Y, Han ZB, Ma J, Zuo C, Geng J, Gong W, Sun Y, Li H, Wang B, Zhang L et al (2012a) A toxicity study of multiple-administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys. *Stem Cells Dev* 21:1401–1408
- Wang Y, Han ZB, Song YP, Han ZC (2012b) Safety of mesenchymal stem cells for clinical application. *Stem Cells Int* 2012:652034
- Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP (2013) A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. *Chest* 143:1590–1598
- Wolfstadt JI, Cole BJ, Ogilvie-Harris DJ, Viswanathan S, Chahal J (2015) Current concepts: the role of mesenchymal stem cells in the management of knee osteoarthritis. *Sports Health* 7:38–44
- Wong KL, Lee KB, Tai BC, Law P, Lee EH, Hui JH (2013) Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years' follow-up. *Arthroscopy* 29:2020–2028
- Wu S, Cui G, Shao H, Du Z, Ng JC, Peng C (2015) The cotransplantation of olfactory ensheathing cells with bone marrow mesenchymal stem cells exerts antiapoptotic effects in adult rats after spinal cord injury. *Stem Cells Int* 2015:516215
- Xia Q, Zhu S, Wu Y, Wang J, Cai Y, Chen P, Li J, Heng BC, Ouyang HW, Lu P (2015) Intra-articular transplantation of atsttrin-transduced mesenchymal stem cells ameliorate osteoarthritis development. *Stem Cells Transl Med* 4:523–531
- Xu Y, Li Z, Li X, Fan Z, Liu Z, Xie X, Guan J (2015) Regulating myogenic differentiation of mesenchymal stem cells using thermosensitive hydrogels. *Acta Biomater* 26:23–33
- Yan SX, Deng XM, Wei W (2013) A big step forward in the treatment of refractory systemic lupus erythematosus: allogeneic mesenchymal stem cell transplantation. *Acta Pharmacol Sin* 34:453–454
- Yang L, Wang Y, Wang X, Liu Y (2015a) Effect of allogeneic umbilical cord mesenchymal stem cell transplantation in a rat model of hepatic cirrhosis. *J Tradit Chin Med* 35:63–68
- Yang SF, Xue WJ, Duan YF, Xie LY, Lu WH, Zheng J, Yin AP (2015b) Nicotinamide facilitates mesenchymal stem cell differentiation into insulin-producing cells and homing to pancreas in diabetic mice. *Transplant Proc* 47:2041–2049
- Yang W, Zheng H, Wang Y, Lian F, Hu Z, Xue S (2015c) Nesprin-1 has key roles in the process of mesenchymal stem cell differentiation into cardiomyocyte-like cells in vivo and in vitro. *Mol Med Rep* 11:133–142
- Yaochite JN, Caliri-Oliveira C, de Souza LE, Neto LS, Palma PV, Covas DT, Malmegrim KC, Voltarelli JC, Donadi EA (2015) Therapeutic efficacy and biodistribution of allogeneic mesenchymal stem cells delivered by intrasplenic and intrapancreatic routes in streptozotocin-induced diabetic mice. *Stem Cell Res Ther* 6:31
- Ye JS, Su XS, Stoltz JF, de Isla N, Zhang L (2015) Signalling pathways involved in the process of mesenchymal stem cells differentiating into hepatocytes. *Cell Prolif* 48:157–165
- Zhang B, Liu R, Shi D, Liu X, Chen Y, Dou X, Zhu X, Lu C, Liang W, Liao L et al (2009) Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. *Blood* 113:46–57
- Zhang W, Ge W, Li C, You S, Liao L, Han Q, Deng W, Zhao RC (2004) Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. *Stem Cells Dev* 13:263–271
- Zhang Z, Lin H, Shi M, Xu R, Fu J, Lv J, Chen L, Lv S, Li Y, Yu S (2012) Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. *J Gastroenterol Hepatol* 27:112–120

- Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang K, Wu X, Zhang Y, Fan Z, Zhou H et al (2015a) Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 21:97–104
- Zhao XF, Xu Y, Zhu ZY, Gao CY, Shi YN (2015b) Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure. *Genet Mol Res* 14:3010–3017
- Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, Deng K, Zhang L, Zou B, Cheng B et al (2014) Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. *Respir Res* 15:39
- Zhong L, Gou J, Deng N, Shen H, He T, Zhang BQ (2015) Three-dimensional co-culture of hepatic progenitor cells and mesenchymal stem cells in vitro and in vivo. *Microsc Res Tech* 78:688–696

Stem Cell Processing

Pham, P.V. (Ed.)

2016, XIII, 225 p. 33 illus., 29 illus. in color., Hardcover

ISBN: 978-3-319-40071-6